Overview
A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®
Status:
Completed
Completed
Trial end date:
2018-06-19
2018-06-19
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
AME is a non-interventional, prospective, longitudinal and multicenter study. This study aims to measure the relationship between antimüllerian hormone serum level (AMH), as measured by a fully automated assay and the initial dose of Menopur® HP-hMG 600 IU/mL prescribed for infertile women undergoing their first IVF/ICSI cycle in the current practice.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ferring PharmaceuticalsTreatments:
Hormones
Menotropins
Criteria
Inclusion Criteria:- Women aged between [18-42] years.
- Both ovaries present.
- Regular menstrual cycles presumed to be ovulatory.
- Primary or secondary infertility of any origin for more than 12 months.
- Patient with at least one result of antimüllerian hormone (AMH) measured by a fully
automated assay available before inclusion, and performed in the past 12 months before
inclusion.
- Candidates eligible to a first IVF/ICSI cycle and for whom Menopur® HP-hMG 600 IU/mL
has been prescribed.
- Having received oral and written information on the study, without any objections for
the use of his/her anonymized data, and having signed a written Informed Consent Form.
Exclusion Criteria:
- Major uterine or ovarian morphological abnormalities or past ovarian surgery.
- Endometriosis stage III/IV.
- Polycystic ovarian syndrome.
- Major endocrine or metabolic abnormalities without treatment.
- Patient included in an interventional study assessing treatment for infertility.